Eli Lilly (LLY)

New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers and some providers, faced considerable downward pressure. This divergence highlights a sector grappling with a flurry of groundbreaking drug

The stock market, as of November 10, 2025, continues its robust rally, defying earlier recessionary fears and exhibiting significant growth across several key sectors. At the heart of this resurgence lies the technology sector, particularly those segments deeply entrenched in artificial intelligence (AI), semiconductors, and cybersecurity. This rally is not

Eli Lilly shares are rising Monday after Leerink Partners upgraded the stock to Outperform and raised its price target to $1,104.

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 4.9% in the afternoon session after Leerink Partners upgraded the stock to Outperform from Market Perform and significantly raised its price target. 

Let's have a look at the top S&P500 gainers and losers in the middle of the day of today's session.

Markets rallied sharply Monday morning as Congress edged closer to a deal that could end the longest U.S. government shutdown in history.

MeiraGTx shares rise after signing a $475 million deal with Eli Lilly for a gene therapy program restoring vision in children with LCA4.

There might still be time to get in on the ground floor.

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 will surely remember that the market’s punishment can be swift and severe when trajectories fall.

For long-term investors, there are plenty of reasons to buy and hold Eli Lilly for not only years but decades.

As of November 2025, Artificial Intelligence (AI) has rapidly transitioned from a futuristic concept to an indispensable tool in American healthcare, profoundly reshaping diagnostics, treatment, and administrative workflows. This transformative leap, however, particularly the increasing reliance on "surrendering care to algorithms," presents a complex ethical landscape and significant societal consequences that demand careful scrutiny and [...]

The weight loss drug company was counted out far too early in the summer, but investors are warming to it again.

The companies announced a huge deal that will have implications for investors.

Pharmaceutical company Organon (NYSE:OGN) will be announcing earnings results this Monday before market hours. Here’s what you need to know.

Eli Lilly stock and a pair of AI plays lead this watch list of stocks near buy points as the S&P 500 makes a stand at a key support level.

The stock didn't stay down for too long.

It could become the first trillion-dollar pharmaceutical company in the process.

Weight loss drugs generated about $10 billion for Lilly in the most recent quarter.

Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."